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SHORT REPORT Open Access
Effect of chemotherapy on the microbiota and
metabolome of human milk, a case report
Camilla Urbaniak1,2, Amy McMillan1,2, Michelle Angelini3, Gregory B Gloor4, Mark Sumarah5,6,
Jeremy P Burton1,2 and Gregor Reid1,2*
Abstract
Background: Human milk is an important source of bacteria for the developing infant and has been shown to
influence the bacterial composition of the neonatal gut, which in turn can affect disease risk later in life. Human
milk is also an important source of nutrients, influencing bacterial composition but also directly affecting the host.
While recent studies have emphasized the adverse effects of antibiotic therapy on the infant microbiota, the effects
of maternal chemotherapy have not been previously studied. Here we report the effects of drug administration on
the microbiota and metabolome of human milk.
Methods: Mature milk was collected every two weeks over a four month period from a lactating woman undergoing
chemotherapy for Hodgkin’s lymphoma. Mature milk was also collected from healthy lactating women for comparison.
Microbial profiles were analyzed by 16S sequencing and the metabolome by gas chromatography–mass spectrometry.
Findings: Chemotherapy caused a significant deviation from a healthy microbial and metabolomic profile, with
depletion of genera Bifidobacterium, Eubacterium, Staphylococcus and Cloacibacterium in favor of Acinetobacter,
Xanthomonadaceae and Stenotrophomonas. The metabolites docosahexaenoic acid and inositol known for their
beneficial effects were also decreased.
Conclusion: With milk contents being critical for shaping infant immunity and development, consideration needs to
be given to the impact of drugs administered to the mother and the long-term potential consequences for the health
of the infant.
Keywords: 16S rRNA gene sequencing, Human milk microbiome, Metabolome
Background
Colonization of the neonatal gut plays a pivotal role in
gastrointestinal, immunological and neurological develop-
ment, with one of the initial sources of bacteria being the
mother’s milk [1,2]. Breastfed infants have been shown to
have lower incidences of asthma, diarrhea, and necrotizing
enterocolitis compared with formula-fed infants [3]. This
protective effect may be due, in part, to the types of bac-
teria present in milk, as infants fed formula supplemented
with probiotics were better protected against these condi-
tions compared to those just fed formula [4-6]. The bac-
teria acquired during infancy can influence disease risk
later in life and play a major role in determining the future
composition of the adult microbiome [5]. Thus, factors
that affect the milk microbiota have important health con-
sequences for the child not only during development but
also into adulthood. In addition to the microbiota, the
metabolites of human milk, such as fatty acids, carbohy-
drates, proteins and vitamins, also play an important role
in infant development and long-term health [7-10].
Post-delivery, many women are prescribed pharmaceutical
agents for various reasons. While most over-the-counter
drugs and antibiotics are not contraindicated during
breast feeding [11,12], when it comes to chemotherapeu-
tics, the recommendation is that breastfeeding should be
avoided until the drug has been cleared from the milk
[13]. In a case report of a 70 mg infusion of cisplatin, no
detectable levels were found in milk after 66 hours [14],
and in another case study using doxorubicin (trade name
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Adriamycin), no detectable levels were seen after 72 hours
[15]. In our particular study, the subject was advised that
breastfeeding could resume 12 days after each chemother-
apy session.
Here we present the first report on the effects of chemo-
therapy on microbial and metabolomic profiles in human
milk over a 4-month period in a breastfeeding woman
undergoing treatment for Hodgkin’s lymphoma (Figure 1).
Methods
Clinical samples and study design
Ethical approval was obtained from Western Research Ethics
Board and Lawson Health Research Institute, London,
Ontario, Canada. Subjects provided written consent for
sample collection and subsequent analyses.
Milk collection and processing
Mature milk was collected from a lactating woman undergo-
ing the ABVD chemotherapy regime (Adriamycin (40 mg),
Bleomycin (16 units), Vinblastine (9.6 mg), Dacarbazine
(600 mg) for Hodgkin’s lymphoma at the London Health
Sciences Center, London, Ontario. Mature milk was also
collected from 8 healthy women recruited from London,
Ontario and the surrounding area. Wearing sterile gloves
the women cleaned their nipple and surrounding area
with sterile saline swabs to reduce the presence of skin
bacteria. Milk was collected using a sterile HygieniKit
Milk Collection System (Ameda, Buffalo Grove, IL, USA)
attached to an electric breast pump. Between 5 and 15 ml
of milk was pumped into a sterile tube and kept on ice
until transfer to the laboratory, which occurred within
1 hour of collection. Samples were aliquoted and stored
at -20°C until DNA extraction.
DNA isolation
After thawing on ice, 2 ml of milk were spun down at
13,000 g for 10 minutes and the supernatant discarded.
The pellet was then homogenized in 1.4 ml of ASL buffer
(QIAamp® DNA Stool Kit, QIAGEN: Valencia, CA, USA)
and 400 mg of 0.1 mm diameter zirconium-glass beads
(BioSpec Products, Bartlesville, OK, USA). Mechanical
and chemical lyses were performed by bead beading at
4,800 rpm for 60 s, then 60 s on ice (repeated twice) using
a mini-beadbeater-1 (BioSpec Products) and then incu-
bated at 95°C for 5 minutes. Subsequent procedures were
performed using the QIAGEN QIAamp® DNA Stool Kit
according to the manufacturer’s protocol, with the excep-
tion of the last step in which the column was eluted with
120 μl of elution buffer. DNA was stored at -20°C until
further use.
V6 16S rRNA gene sequencing
PCR amplification
The genomic DNA isolated from the clinical samples was
amplified using the barcoded primers V6-LT: 5′CCATCT
CATCCCTGCGTGTCTCCGACTCAGNNNNNCWAC
GCGARGAACCTTACC3′ and V6-RT: 5′ CCTCTCTAT
GGGCAGTCGGTGATACRACACGAGCTGACGAC3′,
which amplify the V6 hypervariable region of the 16S rRNA
gene. The PCR was carried out in a 40 μl reaction contain-
ing 5 μl of DNA template (or nuclease-free water as a
negative control), 1.5 mM MgCl2, 0.8 μM of each primer,
4 μl of 10× PCR Buffer (Invitrogen, Burlington, ON,
Canada), 0.2 mM dNTPs, 0.05U Taq Polymerase (Invitrogen)
and 0.15 μg/μl bovine serum albumin. Thermal cycling
was carried out in an Eppendorf Mastercyler under the
following conditions: initial denaturation at 95°C for
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Figure 1 Summary of clinical data and sample collection. Milk samples were collected from a lactating woman undergoing chemotherapy
for Hodgkin’s lymphoma. Milk samples were collected every 2 weeks over a 4-month period. At each session milk was collected 15 to 30 minutes
before (sample A) and after (sample B) chemotherapy. The duration of chemotherapy treatment was 2 hours. No milk was collected at week 8
due to scheduling conflicts.
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2 minutes followed by 25 cycles of 95°C for 1 minute, 55°C
for 1 minute and 72°C for 1 minute. After amplification,
the DNA concentration was measured with the Qubit® 2.0
Fluorometer (Invitrogen) using the broad range assay.
Equimolar amounts of each PCR product were pooled to-
gether and purified using the QIAquick PCR purification
kit (QIAGEN). The PCR purified sample was then sent to
the London Regional Genomics Center, London, Ontario,
Canada for V6 16S rRNA gene sequencing using the Ion
Torrent platform as per the center’s standard operating
procedure.
Sequence processing and taxonomic assignment
Custom Perl and Bash scripts were used to de-multiplex
the reads and assign barcoded reads to individual samples.
Reads were kept if the sequence included a perfect match
to the barcode and the V6 16S rRNA gene primers. Reads
were clustered by 97% identity into operational taxonomic
units (OTUs) using UClust v.3.0.617 [16]. OTUs that rep-
resented ≥1% of the reads in at least one sample were kept,
while those that did not meet the cutoff were discarded.
Taxonomic assignments for each OTU were made by the
Ribosomal Database Project (RDP) SeqMatch tool [17].
From the top 20 matches to the RDP named isolates data-
base, the full taxonomy was retained for matches with the
highest S_ab score. For multiple top matches with equal
scores, the highest common taxonomy was retained (for
example, genus level if multiple species matched equally
well). Since the maximum number of matches displayed
per sequence is 20, the RDP taxonomic assignments were
verified by BLAST against the Greengenes named isolates
database with an output of 100 hits [18]. Taxonomy was
assigned based on hits with the highest percentage iden-
tities and coverage. If multiple hits fulfilled this criterion,
classification was re-assigned to a higher common tax-
onomy. In instances where the highest percentage identity/
coverage yielded a single match, if this were <90% and
the S_ab score from RDP was <0.7, taxonomy was assigned
at the family level instead of at the genus level. A sum-
mary of each OTU classification and its sequence is
shown in Additional file 1. The raw sequencing reads gen-
erated in this study have been deposited to the NCBI
Short Read Archive (SRA) database [SRA:SRP041626].
Data analysis
Weighted UniFrac distances were calculated in QIIME
[19] by using a phylogenetic tree of OTU sequences built
with FastTree [20] and based on an OTU sequence align-
ment with MUSCLE [21]. The QIIME pipeline was also
used to calculate Shannon’s diversity index (logarithms
with base 2) and to generate principal coordinate analysis
(PCoA) plots. Weighted UniFrac distances compare micro-
bial profiles (presence/absence and abundance) between
samples (i.e., beta-diversity) [22] while Shannon’s diversity
index evaluates the microbial diversity within a sample
(i.e., alpha diversity). The higher the Shannon’s diversity
index, the more diverse a sample is and a value of zero in-
dicates the presence of only one species [23]. PCoA plots
allow one to visualize the UniFrac distance matrix and plot
the values on a set of orthogonal axes that capture the
greatest amount of variation between all samples tested.
For beta-diversity analyses, the data set was rarified to the
lowest read count/sample, which was 734 reads. A sum-
mary of clinical data, including total number of sequence
reads per sample, is shown in Additional file 2. Barplots,
boxplots and stripcharts were all generated in R [24].
Statistical analysis
The ALDEx R package version 2 [25] was used to com-
pare genera between the non-treatment and chemother-
apy treatment groups (as portrayed in the boxplots).
Microbiome data represent proportional distributions
and are thus not independent of each other. This means
that a decrease in one organism will inevitably lead to a
concomitant increase in another organism. For example, if
a sample has two organisms A (50%) and B (50%) and A is
completely killed by an antibiotic, the proportion of B in
that sample will now be 100% even if its actual abun-
dance has not changed. The ALDEx R package estimates
the technical variation inherent in high-throughput se-
quencing by Monte-Carlo sampling from a Dirichlet distri-
bution [26]. The Monte-Carlo replicates are transformed
using the centered log-ratio transformation, which takes
the logarithm of the Monte-Carlo estimates of organism
abundances in each sample divided by the per-sample
geometric mean organism abundance [27]. This trans-
formation has several desirable properties that do not exist
in proportional data, notably subcomposition coherence
and linear sample independence. Data transformed in this
way permit the use of standard statistical tests to deter-
mine significance. Values reported in this manuscript rep-
resent the expected values of 128 Dirichlet Monte-Carlo
instances. A value of zero indicates that organism abun-
dance is equal to the geometric mean abundance. Thus,
organisms more abundant than the mean will have posi-
tive values and those less abundant than the mean will
have negative values. Base 2 was used for the logarithm so
differences between values represent fold changes. Statis-
tical significance for these comparisons was determined
by a Mann-Whitney U test with P < 0.05 and a false dis-
covery rate (FDR) of < 0.1 using the q values output by the
fdrtool R package [24].
The unpaired Student’s t-test was used to compare
Shannon’s diversity index (P < 0.05).
Sample preparation gas chromatography-mass spectrometry
To extract metabolites, 100 μl of milk were mixed with
400 μl pure methanol. Samples were vortexed for 15 s
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and centrifuged for 10 minutes at 9,000 g. Supernatants
(200 μl) were transferred to gas chromatography-mass
spectrometry (GC-MS) vials and 2.5 μl of ribitol solution
(2 mg/ml) was added to each vial as an internal standard.
Samples were dried to completeness using a SpeedVac.
After drying, 100 μl of 2% methoxyamine•HCl in pyridine
(MOX) was added to each sample for derivitization
and samples were incubated at 50°C for 90 minutes.
N-methyl-N-(trimethylsilyl) trifluoroacetamide (100 μl)
was then added to each vial and incubated at 50°C
for 30 minutes. Samples were transferred to microin-
serts before running on GC-MS (Agilent 7890A GC,
5975 inert MSD with triple axis detector, 30 m DB5-MS
column with 10 m duraguard column). Samples were run
using 1 μl injections on scan mode and a solvent delay
of 10 minutes. Run time was 60 minutes per sample.
Each sample was run twice non-consecutively to en-
sure consistency throughout the sequence.
GC-MS data analysis
Chromatogram files were converted to ELU format using
the AMDIS Mass Spectrometry software [28]. Chromato-
grams were aligned and abundance of metabolites calcu-
lated using the Spectconnect software [29] with the support
threshold set to low. In order to determine if differences
between week 0 and chemotherapy (weeks 2 to 16) existed,
principle component analysis (PCA) was conducted in
SIMCA (Umetrics, San Jose, CA, USA) using the relative
abundance matrix output from Spectconnect. Data were
mean centered and pareto scaled prior to PCA. Inde-
pendent unpaired t-tests with Bonferroni correction were
calculated in Excel to determine metabolites that were sig-
nificantly altered by chemotherapy (P < 0.05). Compounds
that also contributed to the separation of week 0 from
chemotherapy samples according to the PCA loadings
plot (compounds in bottom left quadrant) were chosen
for further investigation.
Findings
Chemotherapy affected both bacterial diversity and bac-
terial profiles in human milk. Bacterial diversity within
samples was lower in milk collected throughout chemo-
therapy compared with milk samples collected at week 0
and from healthy lactating women (Figure 2). Bacterial
profiles at week 0 were similar to those from healthy
women, although this changed within 2 weeks of treat-
ment (Figure 3A). Samples collected at weeks 4 to 16
shared similar profiles and differed from week 2 and from
week 0/healthy samples (Figure 3A). These differences
were not due to natural changes over time, as the bacterial
community in two milk samples analyzed from a healthy
subject did not change over a 4-month period (Figure 3A,
green samples). The bar plot in Figure 3B shows the
bacterial communities present in these samples with a
striking increase in abundances of Acinetobacter and
Xanthomonadaceae in milk collected during chemother-
apy. A comparison of relative abundances of Acinetobacter,
Xanthomonadaceae and Stenotrophomonas (a genus be-
longing to the Xanthomonadaceae family) between the
chemotherapy (weeks 4 to 16) and non-treatment (week 0
and healthy samples) groups is displayed in Figure 4 and
were significantly higher during chemotherapy. We also
examined the differences between three bacteria believed
to confer beneficial health effects to the infant, Bifidobac-
terium, Eubacterium and Lactobacillus. The first two were
significantly decreased during chemotherapy whereas no
differences were observed for Lactobacillus (Figure 4).
Overall, a total of 22 out of the 49 genera identified
were differentially abundant between the two groups
(Additional file 3). While the core microbiome (that is,
taxa that were present in 100% of the samples) was some-
what similar between the two groups, it is interesting to
note that Stenotrophomonas was present in every chemo-
therapy sample and Lactobacillus and Eubacterium were
present in every healthy and week 0 sample (Additional
file 4).
The metabolic profile also changed as a result of chemo-
therapy (Figure 5) and was similar between weeks 2
and 16, but different to that observed at week 0. A
total of 226 metabolites were detected by our GC-MS
method, 12 of which were significantly different between
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Figure 2 Changes in bacterial diversity as a result of
chemotherapy. Bacterial diversity within a sample (i.e. alpha
diversity) was measured by calculating Shannon’s diversity index.
Each point on the graph represents a subject with the line
representing the mean for all samples within a group. The
higher the index the greater the bacterial diversity found within a
sample. The mean of the ‘Wk0/H’ group (week 0 and healthy samples)
was 4.3, and that of the chemotherapy group (weeks 2 to 16) was 2.8.
Groups were statistically different from each other as measured by
unpaired Student’s t-test (P < 0.05).
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Figure 3 (See legend on next page.)
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Figure 3 16S rRNA sequencing analysis of bacteria in human milk. Milk samples were collected from a lactating woman undergoing
chemotherapy as described in Figure 1 as well as from eight healthy lactating women. (A) Weighted UniFrac PCoA plot. Each milk sample,
represented by a coloured circle, is plotted on this three-dimensional, three-axis plane representing 84% of the variation observed between all
samples. Samples that cluster together are similar in biota composition and abundance. Orange circles represent samples collected from weeks 4
to 16 of chemotherapy, blue circles represent samples collected at week 2 of chemotherapy, purple circles represent samples collected at week 0,
red circles represent milk samples from healthy lactating women (only one time point) and green circles represent milk samples from a healthy
lactating women collected 4-months apart. As shown by the plot, there were three distinct groups: (i) week 0 samples and healthy milk samples;
(ii) week 2 of chemotherapy; and (iii) weeks 4 to 16 of chemotherapy. Data were rarified to 735 reads/sample. (B) Barplot showing the relative
abundances of different genera in each sample. Each bar represents a subject and each coloured box a different genus. The height of the
coloured boxes represents the relative abundance of that genus within the sample. Genera that were less than 2% abundant in a given sample
were placed in the ‘Remaining fraction’ at the top of the graph (grey boxes).
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Figure 4 Comparison of relative proportions of bacterial taxa between treatments. Boxplots comparing six bacterial taxa between samples
collected during chemotherapy (weeks 4 to 16) and those without treatment (week 0 and healthy samples (Wk0/H)). The box signifies the 75%
(upper) and 25% (lower) quartiles and thus shows where 50% of the samples lie. The black line inside the box represents the median. The
whiskers represent the lowest datum still within 1.5 interquartile range (IQR) of the lower quartile and the highest datum still within 1.5 IQR of
the upper quartile. Outliers are shown with open circles. The value ‘0’ represents the geometric mean abundance; thus, values above 0 are more
abundant and values less than 0 are less abundant than the geometric mean. Significant differences were observed between the two groups for
all taxa graphed (Mann-Whitney U test P < 0.05, FDR <0.1).
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the week 0 and chemotherapy (weeks 2 to 16) groups
(Table 1). Additional file 5 shows the relative abun-
dances of all metabolites detected in milk and stripcharts
in Additional file 6 show the distribution of key metabo-
lites detected between the two groups.
Discussion
This study shows that a course of chemotherapy has sig-
nificant effects on bacterial and metabolic profiles in hu-
man milk, moving away from those of healthy lactating
women. Of note, the subject did not report any add-
itional drug use, antibiotics, illness or major changes in
diet over the course of the study.
The consequences of decreased bacterial diversity in
human milk and the implications on the child are still
unknown; however, the decreased milk diversity could
impact intestinal diversity and it has been shown that
low intestinal diversity in the first weeks of life is associated
with necrotizing enterocolitis [30] and an increased risk of
allergy and atopy in school-age children [31]. Lower intes-
tinal diversity has also been observed in children with type
1 diabetes compared to age-matched controls [32].
In addition to overall changes in microbial profiles, we
observed a significant decrease in the relative abundance
of Bifidobacterium in the chemotherapy group com-
pared to the non-treatment group. Bifidobacterium is
Figure 5 Principle component analysis of metabolites in breast milk at week 0 and during chemotherapy. (A) Scoreplot displaying the
distribution of samples based on metabolites alone, where the distance between samples represents how similar the metabolome of those
samples are. Each point represents the average of two technical replicates. (B) Loadings plot. Each point represents a metabolite. Metabolites
present in a given quadrant of the loadings plot are present in highest abundance in samples present in the same quadrant of the scoreplot (A).
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the predominant organism in the gut of breastfed in-
fants, attributed to its ability to metabolize the human
milk oligosaccharides present in large amounts in milk
[33,34]. Maternal levels can also impact gut Bifidobacter-
ium abundance, with low levels in milk correlating with
low levels in the neonatal gut [35]. The potential conse-
quences of decreased numbers of Bifidobacterium being
passed on from the mother to the neonate could be an in-
creased risk of asthma or obesity later in life. High levels of
Bacteroides have been reported in the gut of infants with
low levels of Bifidobacterium [36] and early colonization
with high Bacteroides counts has been associated with an
increased risk of developing asthma and obesity [37-39].
In addition, depleted levels of Bifidobacterium have been
shown to promote colonization of opportunistic patho-
gens such as Klebsiella and Citrobacter [36].
Staphylococcus, including coagulase negative species, are
one of the predominant organisms in human milk [40-42],
and were also significantly reduced as a result of chemo-
therapy. It has been shown that numerous human milk
isolates of Staphylococcus epidermidis can inhibit the
growth of Staphylococcus aureus [43], the main causative
agent of mastitis, which is a painful inflammatory condi-
tion of the breast that often leads to premature cessation
of breastfeeding in many women. While we were not able
to identify the Staphylococcus in our samples down to the
species level with 16S rRNA gene sequencing, culture
analysis on mannitol salt agar plates did show that the
Staphylococcus isolates were not S. aureus and the select
few that were tested were coagulase negative. This reduc-
tion of Staphylococcus (likely coagulase negative species)
as a result of chemotherapy could make lactating women
more prone to infections, affecting both themselves and
their infants. Like Bifidobacterium, Staphylococcus is passed
from the milk to the neonate, with higher numbers in
the intestine of breastfed compared to formula-fed infants
[1]. Interestingly, a metagenome analysis revealed the pres-
ence of immunosuppressive motifs in bacterial DNA
from human milk, with the majority of these belonging
to Staphylococcus [41]. The exposure of the neonate to
this DNA, either ingested from the milk or through live
bacteria that have released their DNA once in the gut,
could help to regulate the infant’s immune response
against a variety of innocuous bacterial, environmental
and food antigens.
The utilization of bacterial products by other bacteria is
termed metabolic cross-feeding and plays an important
role in bacterial selection. For example, the byproducts of
bacterial metabolism, such as lactate and acetate produc-
tion, are utilized as an energy source by many butyrate-
producing bacteria [44-47] such as Eubacterium, which
was decreased in our chemotherapy group. Butyrate is
important for health, as it reduces inflammation and
metabolic diseases, promotes colonic repair and protects
against colon cancer [48,49]. On the other hand, some
pathogens persist and cause disease only in the presence
of certain commensal bacteria [50], likely due to the me-
tabolites produced. Thus, changes in bacterial communi-
ties in human milk will inevitably alter the metabolic
milieu, selecting for bacteria able to utilize those metabo-
lites. As a result, potential shifts from a healthy and bal-
anced intestinal microbiota can occur, having important
consequences on health.
Docosahexaenoic acid (DHA), inositol and an unknown
polyunsaturated fatty acid were among the 12 metabolites
that differed between week 0 and weeks 2 to 16, with re-
duced levels detected during chemotherapy (weeks 2 to
16). DHA is the most abundant long chain polyunsatur-
ated fatty acid in the brain, retina and nerve cells and is
supplied mainly through breast milk [51]. DHA deficien-
cies lead to reduced brain, eye and neuronal development
[51] and it has been observed that breastfed infants have
better visual acuity and neuronal development compared
to those fed formula [52]. Reduced levels of DHA and
alpha-linolenic acid (a precursor of DHA) have been re-
ported in milk of mothers with atopic children compared
to milk from mothers with non-atopic children [53,54].
Another principal metabolite in the neonatal brain is in-
ositol, which is important for osmoregulation, cellular nu-
trition and detoxification [55]. Palmitic acid levels were
also reduced during chemotherapy, though the results
were not significant. Palmitic acid is the most abundant
lipid in human milk and has been shown to increase bone
strength in infants [56] and limit intestinal damage and
pro-inflammatory immune responses in mice [57]. While
changes in metabolite concentrations do occur over the
Table 1 Metabolites significantly altered by
chemotherapy
Metabolite Elevated in Bonferroni corrected
P value
Unknown PUFA Week 0 1.81E-07
DHAa Week 0 0.000304
Arabinose Chemotherapy 0.000456
Threitol Chemotherapy 0.001342
Unknown Chemotherapy 0.002685
Unknown Chemotherapy 0.002768
Decanoic acid Chemotherapy 0.008458
Myristic acid Chemotherapy 0.008727
1-Monopalmitin Chemotherapy 0.009143
Butanal Chemotherapy 0.012356
Unknown Chemotherapy 0.017961
Inositola Week 0 0.037225
aMetabolite identity confirmed by authentic standards. Chemotherapy refers
to samples collected from weeks 2 to 16. Significant differences were
determined using the unpaired Student's t-test, P < 0.05. DHA,
docosahexaenoic acid, PUFA, polyunsaturated fatty acid.
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course of lactation, especially between colostrum and ma-
ture milk, no changes in the above metabolites over the
course of the first year of life have been observed in ma-
ture milk [58-61]. Due to the high variability in milk me-
tabolites between individuals, we did not have enough
samples from healthy women to make substantive claims
as to how the Hodgkin’s patient compared, although there
were no obvious differences in the metabolic profiles of
control samples taken at early compared to later stages of
lactation.
We recognize that the main limitation of the study is
its single case study content of a patient undergoing
chemotherapy. However, the findings were revealing. Of
note, even with the disease, her milk microbiota before
treatment was similar to that of healthy lactating women
and only after intervention did the microbiota patterns
alter. It has been reported by Hunt et al. [40] that the
milk microbiota of a specific individual is stable over
time, consistent with our study from the healthy sample
collected 4 months apart. We believe that the changes in
the microbiota are a result of therapeutic agents and not
specific to just one patient.
Conclusions
Bacterial and metabolic compositions in human milk, so
critical for immunity and infant development, can change
significantly after maternal exposure to chemotherapeutic
agents. Further larger cohort studies are warranted to
examine microbiota and metabolomic changes associated
with chemotherapy and other medications prescribed to
lactating mothers and the consequences for the micro-
biome, the metabolome and long-term health of infants.
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each point on the graph representing a different milk sample. DHA and
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significant. Values represent an average of two technical replicates.
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